



### Introduction

- Artificial tears are commonly recommended by eye care professionals in the management of dry eye disease (DED), regardless of disease severity and subtype.<sup>1</sup>
- I-DROP<sup>®</sup> MGD is a novel formulation of viscoadaptive hyaluronic acid, phosphorylcholine and glycerin to support integration, stabilization and enhancement of the tear film lipid layer, as well as hydration of the ocular surface.

## Purpose

The purpose of this two-part pilot study was to:

- 1. Compare the difference in tear film measures over 2 hours after instilling I-DROP MGD (test) compared with Thealoz Duo (control) – another hyaluronic acid-based lubricant drop.
- 2. Examine the subjective relief of dry eye symptoms with I-DROP MGD over 1 week vs. participants' habitual drops.

## Methods


Ten participants with DED that habitually used artificial tears at least once daily for the past 30 days participated in a two-part study. **Part 1** was a randomized, double-masked study involving contralateral application of test and control drops, followed by a 2-hour observation period of objective non-invasive tear break-up (NITBUT) and tear meniscus height (TMH), assessed using the Keratograph 5M (Oculus, Germany), and lipid layer thickness (LLT), assessed using the TearScience LipiView II (Johnson & Johnson Vision, USA). In **Part 2**, participants were provided with one bottle of I-DROP MGD to use bilaterally at least once daily for 7 days. After 7 days, subjective ratings (0-100 scale, 0=poor

# Examining Symptomatic Relief and Kinetic Tear Film Stability of I-DROP<sup>®</sup> MGD Eye Drops

# Alison Ng<sup>1</sup>, Jaya Dantam<sup>1</sup>, Jill Woods<sup>1</sup>, Blair McEwen<sup>2</sup>, Lyndon Jones<sup>1</sup>

<sup>1</sup>Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo, Canada. <sup>2</sup>I-MED Pharma, Saint-Laurent, QC, Canada

outcome) of comfort, dryness, soothing and quality of vision along with OSDI and SPEED scores were collected and compared with participant's habitual eye drops.



Results

- NITBUT was higher in eyes that 10.5 ± 5.7s, p=0.037).
- TMH was higher in the eyes that 0.29 ± 0.10mm, p=0.005).
- LLT was significantly greater with p=0.005). LLT I-DROP received than eyes less Thealoz Duo (6.5 vs. 12.1nm).

### Figures 1-3: NITBUT, TMH and LLT over two hours (mean, SD). \*p<0.05

received I-DROP MGD from 5 to 90 minutes and was significantly greater than Thealoz Duo at 60-minutes (Fig. 1, 14.2 ± 5.1 vs.

received I-DROP MGD from 5 to 120 minutes and was significantly greater than Thealoz Duo at 5 minutes (Fig. 2, 0.42 ± 0.22 vs.

Thealoz Duo at 5 minutes (Fig. 3, 79.5 ± 15.7 vs. 68.5 ± 13.8nm, eyes that in MGD varied that received

### Part 2: Bilateral, 7-days I-DROP MGD

- Subjective ratings for comfort and soothing were significantly greater with I-DROP MGD compared to habitual drops; no statistically significant differences were found for dryness or quality of vision (Table 1).
- There was a statistically significant and clinically relevant reduction (-12) in OSDI score<sup>2</sup> after using I-DROP MGD for 7 days compared to habitual drops.
- A similar statistically significant reduction (-4) in SPEED score was also observed.


### Table 1: Subjective ratings & questionnaire scores (mean ± SD)


Subjective Rating / Questionnaire	Habitual eye drop	I-DROP M
Queotronnane	шор	
Comfort	73 ± 14	82 ± 6
Dryness	68 ± 17	79 ± 6
Soothing	75± 20	86 ± 8
Quality of vision	81 ± 25	86 ± 10
OSDI	45 ± 15	33 ± 12
SPEED	15 ± 3	11 ± 4

### Conclusions

Over 2 hours, I-DROP MGD generally resulted in longer NITBUT and higher TMH compared to Thealoz Duo. When used for 7 days, I-DROP MGD resulted in clinically relevant reductions in dry eye symptoms, measured with OSDI another hyaluronic acid-based compared to Improvements (>10%) in subjective ratings for comfort and soothing may be considered clinically relevant. References

1. Wolffsohn JS, Travé Huarte S, Jones L, et al. Clinical practice patterns in the management of dry eye disease: A TFOS international survey. Ocul Surf. Jul 2021;21:78-86. 2. Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. Jan 2010;128(1):94-101












UNIVERSITY OF WATERLOO FACULTY OF SCIENCE School of Optometry & Vision Science

## Results



© 2022 CORE – Centre for Ocular Research & Education, University of Waterloo. All rights reserved. All data and images were collected, compiled and are exclusively owned, by CORE. Unauthorized utilization, editing, reproduction or distribution of this poster or any part thereof is strictly prohibited. Email contact for correspondence: alison.ng@uwaterloo.ca

## Examining Symptomatic Relief and Kinetic Tear Film Stability of I-DROP® MGD Eye Drops

<sup>1</sup>Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo, Canada. <sup>2</sup>I-MED Pharma, Saint-Laurent, QC, Canada

### Figures 1-3: NITBUT, TMH and LLT over two hours (mean, SD). \*p<0.05

# Alison Ng<sup>1</sup>, Jaya Dantam<sup>1</sup>, Jill Woods<sup>1</sup>, Blair McEwen<sup>2</sup>, Lyndon Jones<sup>1</sup>